



Pearls From the Experts: Part 2

Impact on Practice Flow

Please refer to the full Prescribing Information for management of IOP.

What made you incorporate DEXYCU® (dexamethasone intraocular suspension) 9% into your practice?

Eric D. Donnenfeld, MD: I very strongly feel that the future of postoperative medications is sustained drug delivery at the site of inflammation. As an industry, I believe providers are beginning to trend away from standard topical medications to intracameral medications like DEXYCU, and I wanted to be ahead of the curve. We pride ourselves at our practice in having the most advanced patient care, and I believe that DEXYCU is one of the main things one can do in their practice to meet patients' needs.

Michael Saidel, MD: My center was part of the original clinical trials for DEXYCU, so we had a great deal of pre-market experience with it. Our positive experience in those trials was what led us to incorporating it into our practice. Additionally, I'm trained in both cornea and uveitis. Thus, I have a keen interest in inflammation control, which is why DEXYCU became even more interesting to me.

INDICATION AND USAGE

DEXYCU® (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Increase in Intraocular Pressure

- Prolonged use of corticosteroids, including DEXYCU, may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision
- Steroids should be used with caution in the presence of glaucoma

Delayed Healing

- The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation
- In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of corticosteroids

Please see continued Important Safety Information on adjacent page.

Has DEXYCU changed the way that your staff prepares for surgery?

Steven M. Silverstein, MD, FACS: During the course of cataract surgery, while the surgeon is performing phacoemulsification, the circulating nurse takes the vial and places it on the vortex shaker, allowing the material to remain as a tight, compact sphere. When the surgeon is ready for the injection at the very last step of the procedure, the nurse already has the fluid drawn up in the syringe, ready to hand over, making the entire process very efficient and not holding up the time of the surgical case.

John A. Hovanesian, MD: DEXYCU has improved the process of preparing for surgery because our staff members spend less time on medication prescriptions, prior authorizations, and instructing patients. There is also a process for evaluating a patient's insurance coverage. For Medicare Part B patients, it's fairly trivial because we know it's going to be covered for them. For commercial payers, we're seeing fairly consistent and increasing coverage, so our staff is familiar with which plans pay.

EyePoint wants patients to be able to receive this medication and not have to pay out of pocket for it. Because of that, EyePoint is interested in making things easy for our staff and has put in place a very effective access program that helps our staff ensure that our surgery center will be reimbursed for the DEXYCU that we use.



In part 2 of this three-part series, Eric D. Donnenfeld, MD; Steven M. Silverstein, MD, FACS; Michael Saidel, MD; and John A. Hovanesian, MD, explore why they decided to give DEXYCU (EyePoint Pharmaceuticals) a chance, as well as how DEXYCU has impacted their practice flow.



ERIC D. DONNENFELD, MD



JOHN A. HOVANESIAN, MD



MICHAEL SAIDEL, MD



STEVEN M. SILVERSTEIN, MD, FACS

“DEXYCU has improved the process of preparing for surgery because our staff members spend less time on medication prescriptions, prior authorizations, and instructing patients.”

—John A. Hovanesian, MD

Who pre-certifies patients' eligibility for DEXYCU?

Dr. Silverstein: Most surgery centers do not have the staffing necessary to perform pre-certification. In our practice, the pre-certification process for the use of DEXYCU is taken on by the billing staff. Once a patient has been certified and approved for the use of DEXYCU, this information is given to the surgical counselor who relates this to the surgery center staff so they can prepare and pull the product in preparation for that patient's unique and individual surgical experience. ■

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Exacerbation of Infection

- The use of DEXYCU, as with other ophthalmic corticosteroids, is not recommended in the presence of most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures
- Use of a corticosteroid in the treatment of patients with a history of herpes simplex requires caution and may prolong the course and may exacerbate the severity of many viral infections
- Fungal infections of the cornea are particularly prone to coincidentally develop with long-term local steroid application and must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate
- Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection

Cataract Progression

- The use of corticosteroids in phakic individuals may promote the development of posterior subcapsular cataracts

ADVERSE REACTIONS

- The most commonly reported adverse reactions occurred in 5-15% of subjects and included increases in intraocular pressure, corneal edema and iritis

Please see brief summary of full Prescribing Information on adjacent page and full Prescribing Information at DEXYCU.com/PI.

ERIC D. DONNENFELD, MD

- Professor of Ophthalmology, New York University, New York
- Trustee, Dartmouth Medical School, Hanover, New Hampshire
- Founding Partner, OCLI Vision, New York
- CRST Editor Emeritus
- ericdonnenfeld@gmail.com
- Financial disclosure: Consultant (Allergan/AbbVie, EyePoint Pharmaceuticals, Novartis, Ocular Therapeutix)

JOHN A. HOVANESIAN, MD

- Private practice, Harvard Eye Associates, Laguna Hills, California
- Clinical Instructor, Jules Stein Eye Institute, University of California, Los Angeles
- Member, CRST Editorial Advisory Board
- jhovanesian@mdbackline.com; Twitter @DrHovanesian
- Financial disclosure: Founder (MDbackline)

MICHAEL SAIDEL, MD

- North Bay Eye Associates, Petaluma, California
- Clinical Instructor, California Pacific Medical Center
- msaidel@northbayeye.com
- Financial disclosure: Speaker (Bausch + Lomb, EyePoint Pharmaceuticals, Sun Pharmaceuticals)

STEVEN M. SILVERSTEIN, MD, FACS

- President, Silverstein Eye Centers, Kansas City, Missouri
- Assistant Clinical Professor of Ophthalmology, University of Missouri School of Medicine, Kansas City
- ssilverstein@silversteineyecenters.com
- Financial disclosure: Researcher, lecturer, and advisor (Omeros)